Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics

Autor: Sanchez-Martinez V, Romero-Rubio D, Jose Abad-Perez M, Amparo Descalzo-Cabades M, Alonso-Gutierrez S, Salazar-Fraile J, Montagud V, Facila L

Publikováno v: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname

Background: People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::981b093774074312d57912fe30745a51
https://fundanet.fihgu.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1355